Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 19

1.

The immune response during acute HIV-1 infection: clues for vaccine development.

McMichael AJ, Borrow P, Tomaras GD, Goonetilleke N, Haynes BF.

Nat Rev Immunol. 2010 Jan;10(1):11-23. doi: 10.1038/nri2674. Epub 2009 Dec 11. Review.

2.

HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation.

Chomont N, El-Far M, Ancuta P, Trautmann L, Procopio FA, Yassine-Diab B, Boucher G, Boulassel MR, Ghattas G, Brenchley JM, Schacker TW, Hill BJ, Douek DC, Routy JP, Haddad EK, Sékaly RP.

Nat Med. 2009 Aug;15(8):893-900. doi: 10.1038/nm.1972. Epub 2009 Jun 21.

3.

The challenge of finding a cure for HIV infection.

Richman DD, Margolis DM, Delaney M, Greene WC, Hazuda D, Pomerantz RJ.

Science. 2009 Mar 6;323(5919):1304-7. doi: 10.1126/science.1165706. Review.

PMID:
19265012
4.

Persistence of HIV in gut-associated lymphoid tissue despite long-term antiretroviral therapy.

Chun TW, Nickle DC, Justement JS, Meyers JH, Roby G, Hallahan CW, Kottilil S, Moir S, Mican JM, Mullins JI, Ward DJ, Kovacs JA, Mannon PJ, Fauci AS.

J Infect Dis. 2008 Mar 1;197(5):714-20. doi: 10.1086/527324.

PMID:
18260759
5.

Decay of the HIV reservoir in patients receiving antiretroviral therapy for extended periods: implications for eradication of virus.

Chun TW, Justement JS, Moir S, Hallahan CW, Maenza J, Mullins JI, Collier AC, Corey L, Fauci AS.

J Infect Dis. 2007 Jun 15;195(12):1762-4. Epub 2007 May 2.

PMID:
17492591
6.

The survival benefits of AIDS treatment in the United States.

Walensky RP, Paltiel AD, Losina E, Mercincavage LM, Schackman BR, Sax PE, Weinstein MC, Freedberg KA.

J Infect Dis. 2006 Jul 1;194(1):11-9. Epub 2006 Jun 1.

PMID:
16741877
7.

HIV-infected individuals receiving effective antiviral therapy for extended periods of time continually replenish their viral reservoir.

Chun TW, Nickle DC, Justement JS, Large D, Semerjian A, Curlin ME, O'Shea MA, Hallahan CW, Daucher M, Ward DJ, Moir S, Mullins JI, Kovacs C, Fauci AS.

J Clin Invest. 2005 Nov;115(11):3250-5.

8.

Depletion of latent HIV-1 infection in vivo: a proof-of-concept study.

Lehrman G, Hogue IB, Palmer S, Jennings C, Spina CA, Wiegand A, Landay AL, Coombs RW, Richman DD, Mellors JW, Coffin JM, Bosch RJ, Margolis DM.

Lancet. 2005 Aug 13-19;366(9485):549-55.

9.

Heterogeneous clearance rates of long-lived lymphocytes infected with HIV: intrinsic stability predicts lifelong persistence.

Strain MC, Günthard HF, Havlir DV, Ignacio CC, Smith DM, Leigh-Brown AJ, Macaranas TR, Lam RY, Daly OA, Fischer M, Opravil M, Levine H, Bacheler L, Spina CA, Richman DD, Wong JK.

Proc Natl Acad Sci U S A. 2003 Apr 15;100(8):4819-24. Epub 2003 Apr 8.

10.

Intensification and stimulation therapy for human immunodeficiency virus type 1 reservoirs in infected persons receiving virally suppressive highly active antiretroviral therapy.

Kulkosky J, Nunnari G, Otero M, Calarota S, Dornadula G, Zhang H, Malin A, Sullivan J, Xu Y, DeSimone J, Babinchak T, Stern J, Cavert W, Haase A, Pomerantz RJ.

J Infect Dis. 2002 Nov 15;186(10):1403-11. Epub 2002 Oct 29.

PMID:
12404155
11.

Immune control of HIV-1 after early treatment of acute infection.

Rosenberg ES, Altfeld M, Poon SH, Phillips MN, Wilkes BM, Eldridge RL, Robbins GK, D'Aquila RT, Goulder PJ, Walker BD.

Nature. 2000 Sep 28;407(6803):523-6.

PMID:
11029005
12.

Persistence of episomal HIV-1 infection intermediates in patients on highly active anti-retroviral therapy.

Sharkey ME, Teo I, Greenough T, Sharova N, Luzuriaga K, Sullivan JL, Bucy RP, Kostrikis LG, Haase A, Veryard C, Davaro RE, Cheeseman SH, Daly JS, Bova C, Ellison RT 3rd, Mady B, Lai KK, Moyle G, Nelson M, Gazzard B, Shaunak S, Stevenson M.

Nat Med. 2000 Jan;6(1):76-81.

PMID:
10613828
13.

HIV-1 and T cell dynamics after interruption of highly active antiretroviral therapy (HAART) in patients with a history of sustained viral suppression.

Davey RT Jr, Bhat N, Yoder C, Chun TW, Metcalf JA, Dewar R, Natarajan V, Lempicki RA, Adelsberger JW, Miller KD, Kovacs JA, Polis MA, Walker RE, Falloon J, Masur H, Gee D, Baseler M, Dimitrov DS, Fauci AS, Lane HC.

Proc Natl Acad Sci U S A. 1999 Dec 21;96(26):15109-14.

14.

Re-emergence of HIV after stopping therapy.

Chun TW, Davey RT Jr, Engel D, Lane HC, Fauci AS.

Nature. 1999 Oct 28;401(6756):874-5. No abstract available.

PMID:
10553903
15.

Effect of interleukin-2 on the pool of latently infected, resting CD4+ T cells in HIV-1-infected patients receiving highly active anti-retroviral therapy.

Chun TW, Engel D, Mizell SB, Hallahan CW, Fischette M, Park S, Davey RT Jr, Dybul M, Kovacs JA, Metcalf JA, Mican JM, Berrey MM, Corey L, Lane HC, Fauci AS.

Nat Med. 1999 Jun;5(6):651-5.

PMID:
10371503
16.

Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy.

Zhang L, Ramratnam B, Tenner-Racz K, He Y, Vesanen M, Lewin S, Talal A, Racz P, Perelson AS, Korber BT, Markowitz M, Ho DD.

N Engl J Med. 1999 May 27;340(21):1605-13.

17.

Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy.

Chun TW, Stuyver L, Mizell SB, Ehler LA, Mican JA, Baseler M, Lloyd AL, Nowak MA, Fauci AS.

Proc Natl Acad Sci U S A. 1997 Nov 25;94(24):13193-7.

18.

Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy.

Finzi D, Hermankova M, Pierson T, Carruth LM, Buck C, Chaisson RE, Quinn TC, Chadwick K, Margolick J, Brookmeyer R, Gallant J, Markowitz M, Ho DD, Richman DD, Siliciano RF.

Science. 1997 Nov 14;278(5341):1295-300.

19.

Recovery of replication-competent HIV despite prolonged suppression of plasma viremia.

Wong JK, Hezareh M, Günthard HF, Havlir DV, Ignacio CC, Spina CA, Richman DD.

Science. 1997 Nov 14;278(5341):1291-5.

Supplemental Content

Support Center